iTeos Therapeutics, Inc.
DelistedCIK 1808865fmd_133G693QGS580604FVWCPVBBGBManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Jun 30, 2025, 26 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | 345 | 268 | 13 | 35 |
| Research and development | 19 | 30 | 59 | 97 | 113 | 145 |
| Total operating expenses | 28 | 45 | 100 | 141 | 164 | 195 |
| Operating income | (28) | (45) | 245 | 126 | (151) | (160) |
| Other non-operating income (expense) | (0) | (0) | 1 | 8 | 4 | 3 |
| Income before taxes | (22) | (38) | 256 | 149 | (109) | (120) |
| Income tax expense | (0) | (0) | 42 | 52 | 4 | 14 |
| Net income from continuing operations | (22) | (43) | 215 | 97 | (113) | (134) |
| Net income | (22) | (38) | 215 | 97 | (113) | (134) |
| Net income to common shareholders | (27) | (43) | 215 | 97 | (113) | (134) |